For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Information and products associated with cytokine storm in novel coronavirus research

Related

  • COVID-19 research information and products
    • Curated COVID-19 resources
      • Supporting our customers and employees during the COVID-19 outbreak
        • SARS-CoV-2 structure and cell entry
          • Blood-based biomarkers for COVID-19
            • SARS-CoV-2 spike protein antibodies in research

              Cytokine storms have been shown to be common pathologies in severe SARS-CoV-2 infections. 

              Updated June 29, 2022

              The pathologies and symptoms of COVID-19 have been shown to be highly heterogeneous, with many of the immunological determinants of disease progression and prognosis still unknown. Severe cases of COVID-19 typically present with high viral loads, respiratory distress, and pulmonary damage that correlate with increases in cytokine levels. Termed cytokine storm syndrome (CSS), excessive cytokine release is a key driver of the acute respiratory distress syndrome (ARDS), which is thought to be the leading cause of COVID-19 mortality1.

              For an overview of immune cell signaling and cytokine targets, download our interactive poster.

              Download cytokine storm in COVID-19 poster.

              Cytokine storm in COVID-19

              Cytokines coordinate the body's response to infection and damage, triggering inflammation. However, in some cases, cytokines can be released in excessive or uncontrolled amounts, causing harm to the body. Cytokine storm syndromes can lead to vital organ failure, including of the cardiac, lung and renal systems, and result in death. Initial evidence from China demonstrated elevated levels of the cytokines IL-6, IL-2R, CRP and ferritin in severe cases of SARS-CoV-2 infection2-4. Further studies have since highlighted persistently raised levels of many additional cytokines, including TNF-alpha, IP-10, MCP-3, and IL-1RA in severe cases4, 5.

              Researchers are analyzing potential treatments for the cytokine storm response seen in patients, of which dexamethasone has been shown as to be a cost-effective treatment. An alternative approach may be through targeting tumor necrosis factor-alpha (TNF-alpha)6: an important cytokine in nearly all acute inflammatory reactions and a frequently elevated biomarker in the blood and tissues of COVID-19 patients7. Other targets that have been under investigation include TLR4, IFN, IL1, IL6, and CSF.


              For an overview of the cytokine response in COVID-19 download our poster.

              Our antibodies and proteins specific for the detection and analysis of human coronaviruses can be found here. 

              If there is a product you need for COVID-19 research that is not listed here, please contact us and we may be able to help.


              See a full range of cytokine products for your research

              Antibodies | Proteins | ELISA kits | Cell lines


              Abcam’s products are intended for research use only, not for use in diagnostic, therapeutic or any other purposes.


              ​References

              1. Hojyo, S., Uchida, M, and Tanaka, K. et al. How COVID-19 induces cytokine storm with high mortality. BMC Inflammation and Regeneration. (2020) 40;37. https://doi.org/10.1186/s41232-020-00146-3
              2. ​Chen L, Liu HG, Liu W et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chinese Journal of Tuberculosis and Respiratory Diseases. (2020)  43(0):E005.
              3. Wenjun Wang Jr., Jianxing He, Puyi Lie, et al. The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis. medRxiv (2020) https://doi.org/10.1101/2020.02.26.20026989
              4. Ruan Q, Yang K, Wang W., et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine (2020) https://doi.org/10.1007/s00134-020-06028-z
              5. Yang Y, Shen C, Li J, et al. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv (2020) https://doi.org/10.1101/2020.03.02.20029975
              6. Pederson SF and Ho YC. SARS-CoV-2: A storm is raging. J. Clinic. Invest. (2020) pii:137647.​ 
              7. Feldmann M, Maini RN, Woody JN et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020 (published online Apr 9) doi: 10.1016/S0140-6736(20)30858-8. 

              8. ​Wang L, He W, Yu X et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020; (published online March 30.) DOI:10.1016/j.jinf.2020.03.019

              9. Gerriets V, Bansal P, Khaddour K. Tumor necrosis factor (TNF) inhibitors. Publishing, Treasure Island, FL2020

                ​












































              The outbreak of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, represents a major global threat to public health. Patient symptoms and responses to COVID-19 are highly heterogeneous, and the immunological determinants of poor prognosis remain unknown. Severe cases of COVID-19 present with high viral loads, respiratory distress and pulmonary damage that correlate with surges in patient cytokine levels, termed cytokine storm syndrome. 

              Cytokine storm in COVID-19

              ​​​Cytokines coordinate the body's response to infection and trigger inflammation, but in some cases, as seen with COVID-19, they appear to be released in excessive or uncontrolled amounts. This cytokine storm can lead to vital organ failure, including of the cardiac, lung and renal systems, and result in death. Initial evidence from China demonstrated elevated levels of the cytokines IL-6, IL-2R, CRP and ferritin in severe cases of SARS-CoV-2 infection.1,2,3 

              Further studies have highlighted persistently raised levels of the additional cytokines IP-10, MCP-3, and IL-1RA in severe patient cases of COVID-19.4 New research is rapidly accumulating around cytokine storms as a key biological response to SARS-CoV-2 infection. 

              Research to profile patient responses and advance our understanding is essential to aid in the development of effective diagnostic, prognostic and therapeutic solutions for COVID-19. 
              Get resources and offers direct to your inbox Sign up
              A-Z by research area
              • Cancer
              • Cardiovascular
              • Cell biology
              • Developmental biology
              • Epigenetics & Nuclear signaling
              • Immunology
              • Metabolism
              • Microbiology
              • Neuroscience
              • Signal transduction
              • Stem cells
              A-Z by product type
              • Primary antibodies
              • Secondary antibodies
              • Biochemicals
              • Isotype controls
              • Flow cytometry multi-color selector
              • Kits
              • Loading controls
              • Lysates
              • Peptides
              • Proteins
              • Slides
              • Tags and cell markers
              • Tools & Reagents
              Help & support
              • Support
              • Make an Inquiry
              • Protocols & troubleshooting
              • Placing an order
              • RabMAb products
              • Biochemical product FAQs
              • Training
              • Browse by Target
              Company
              • Corporate site
              • Investor relations
              • Company news
              • Careers
              • About us
              • Blog
              Events
              • Tradeshows
              • Conferences
              International websites
              • abcam.cn
              • abcam.co.jp

              Join with us

              • LinkedIn
              • facebook
              • Twitter
              • YouTube
              • Terms of sale
              • Website terms of use
              • Cookie policy
              • Privacy policy
              • Legal
              • Modern slavery statement
              © 1998-2023 Abcam plc. All rights reserved.